Summary Histamine has recently been shown to be a growth factor for some gastric and colorectal cancer cells. Previous studies have shown that cimetidine blocks in vitro and in vivo histamine-stimulated growth and cAMP release from the human colonic cancer cell line, C170. In this study, ranitidine, another H2 receptor antagonist, did not affect either basal or histamine-stimulated in vitro proliferation of C170, and failed to prevent cAMP release in vitro. Ranitidine did not inhibit in vivo growth of C170 at a dose of 1, 10, 25, 50 or 100 mg kg-', in contrast to 50 mg kg -day-' cimetidine, which produced 39.3% inhibition of tumour volume (P<0.01) after 23 days' treatment. Ranitidine did not inhibit in vivo histamine-stimulated growth of C170 cells.
We recently reported that histamine is a growth factor for some colorectal cancer cell lines (Adams et al., 1994a) . The histamine receptor antagonist, cimetidine, has been found to significantly slow the growth of experimentally induced gastrointestinal cancers (Adams et al., 1993 Watson et al., 1993) and improve survival in patients with gastrointestinal malignancies (Tonnesen et al., 1988; Matsumotos, 1995) . Whether this is due to the inhibitory effect of cimetidine on suppressor Tlymphocyte activity (Osband et al., 1981) , its stimulation of natural killer (NK) cell activity (Hellstrand and Hermodsson, 1986; Allen et al., 1987; Kikuchi et al., 1985) , its stimulation of interleukin 2 production in helper T cells (Gifford and Tilberg, 1987) or its blocking of the direct mitogenic effect of histamine on colon cancer , is unknown.
Ranitidine is a more potent and clinically well-tolerated histamine H2 receptor antagonist than cimetidine. There has been some conflict in the literature as to whether ranitidine and cimetidine have similar effects on the immune system (Nielson et al., 1989a, b; Halm et al., 1995) .
The effects of ranitidine on cancer growth are not well investigated. The aim of this paper was to examine the effect of ranitidine on the growth of colon cancer, and its effect on the histamine-sensitive human colorectal cancer cell lines, C170 and LIM2412.
Method
Cell lines C170 cells are an adherent cell line (Durrant et al., 1986) , which were derived from a patient with a Dukes' C colonic adenocarcinoma (CRC Laboratories, Nottingham, UK). LIM2412 cells are a suspension cell line with some adherent cells present (Whitehead et al., 1992) . This cell line was derived from a patient diagnosed with a poorly differentiated colonic adenocarcinoma (Ludwig Institute, Melbourne, Australia). Both these cell lines were grown in RPMI-1640 with 10% fetal calf serum (FCS) under 5% carbon dioxide and refed twice weekly.
In vitro cell proliferation assay Cells were resuspended in serum containing RPMI-1640 at a concentration of 1 x 104 cells 0.2 ml-1 and incubated overnight in a 96-well microtitre plate. The supernatant was then removed and replaced with 0.6 imol of thymidine (Sigma, St Louis, MO, USA) in serum-free media. After 24 h the supernatant was removed and replaced with histamine (Sigma) and/or ranitidine hydrochloride (Glaxo, Greenford, UK) in serum-free media with untreated controls. Ranitidine was added in replicates of at least three, over a concentration range of 1 x 10-9 M to 1 X 10-6 M. Histamine was added to the cells with/without ranitidine at a concentration range of 1 x 10-9 M to 1 x 10-7 M as 1 x 10-8 M most frequently achieved maximal stimulation . Each experiment was repeated three times. As a direct measure of DNA replication (Kusyk et al., 1986) , 0.1 pCi of methyl-['H]-thymidine (DuPont, NEN, Boston, MA, USA) was added to the wells and incubated for a further 8, 24 and 48 h. The cells were then harvested using a cell harvester (PHD cell harvester, Cambridge Technology, USA) and counted using a beta-counter (Minaxi Tri-carb 4000 series, United Technologies Packard, USA).
Statistical analysis
Results were calculated as a mean percentage of the control (s.e.). Any statistical differences were calculated using a oneway analysis of variance (ANOVA). A P-value of less than 0.05 was considered significant.
Quantification of intracellular cyclic adenosine monophosphate (cAMP) Intracellular cAMP was measured using a monoclonal antibody-based kit (Amersham, UK). C170 cells were harvested and resuspended in serum-free RPMI-1640 with 0.5 mM isobutyl methylxanthine (IBMX, Sigma) at 1.25 x 105 cells 0.25 ml-', and incubated in polypropylene tubes at 37°C for 10 min. Histamine aliquots of 0.125 ml were added at a concentration range of 1 x 10-' to 1 x 10-3 M, with or without the addition of ranitidine at 1 x 10-4 M. Forskolin, a direct stimulator of adenylate cyclase (Seamon and Daly, 1981) , was added in triplicate at a final concentration of 1 x 10-6 M. Following the addition of histamine, the cells were incubated for 10 min at 37°C (Shanin et al., 1985) 
Results
In vitro: C170 Ranitidine had no effect on basal growth in five experiments in which histamine produced a stimulation in cell proliferation, of which three were significant (P<0.05) to a maximum of 142.8% of control at 1 X 10-8 M histamine (Table I) . Ranitidine, at a concentration of 1 x 10-8 to 1 x 10-6 M, failed to inhibit the histamine-stimulated cell proliferation. Histamine did not stimulate cell proliferation in assays shorter than 48 h (data not shown).
LIM2412
Neither histamine nor ranitidine affected basal growth of LIM2412 cells. Because of our inability to show a significant in vitro stimulation with histamine we were unable to study the effect of ranitidine on histamine-stimulated in vitro growth (data not shown).
Quantification of intracellular cAMP, C170
The addition of histamine alone to C170 cells significantly stimulated cAMP production in a dose-dependent manner. This effect was antagonised by cimetidine (Figure 1 ). In contrast, ranitidine did not inhibit histamine-stimulated cAMP release. 
Effect of ranitidine and cimetidine on basal C170 growth in vivo
The administration of oral ranitidine to mice bearing C170 tumours had no effect at 1 or 10 mg kg-' day-' (Figure 2 ). Higher doses of ranitidine (25, 50 or 100 mg kg-' day-') also had no effect on tumour growth (data not shown). This is in contrast to tumours in animals receiving cimetidine at a dose of 50 mg kg-' day-', which were inhibited maximally to 48.4% of the control after 18 days' treatment (P=0.019) (Figure 2) .
Effect of histamine, cimetidine and ranitidine on in vivo LIM2412 growth
The administration of 50 mg kg-' day-' ranitidine to mice bearing LIM2412 tumours produced significant stimulation in tumour growth of 90.6% (P<0.01) (Figure 3 ) and 98.4% (P<0.01) (Figure 4 ) of the untreated control in two separate experiments. Ranitidine (25 mg kg-') produced some stimulation but was not significant (P = 0.12) whereas 10 mg kg-' ranitidine had no effect (P=0.77) (Figure 3) . Cimetidine, at a dose of 100 mg kg-' day-' produced a significant stimulation of 94.9% (P= 0.014) (Figure 4) data not shown).
Discussion
Ranitidine had no effect on either basal or histaminestimulated growth of C170 either in vitro or in vivo and had no effect on histamine-stimulated cAMP production. This is in marked contrast to the effects of cimetidine, another H2 receptor antagonist, which we have found in this series of experiments and previously to inhibit histaminestimulated C170 growth in vitro and in vivo, as well as being Figure 4 Effect of histamine (1.2 x 10-7 M day-), ranitidine (50 mg kg-day-1) and cimetidine (I00 mg kg-l day-1) on the in vivo growth of LIM2412. Histamine was administered via a 14 day subcutaneous mini-osmotic pump that was replaced after 14 days (Alza Corporation, Palo Alto, CA, USA). Results were expressed as the mean (s.e.) tumour volumes on various days after tumour inoculation. A one-way ANOVA was used to determine any differences between treatment groups after 23 days' treatment. Histamine and cimetidine significantly stimulated tumour growth (*P <0.05). Ranitidine significantly stimulated tumour growth (**P<0.01). 0, Control (n=18); b, histamine (1.2 x 10-7M day-') (n= 10); 0, cimetidine (I00mgkg' day-) (n = 11); A, ranitidine (50 mg kg-1 day-') (n = 13).
able to inhibit histamine-stimulated cAMP production by C170 cells (Adams et al., 1994a) .
These results are surprising because ranitidine is a 4-9 times more potent antagonist at the H2 receptor than cimetidine on the parietal cell (Woodings et al., 1983 ). This suggests a mechanism of action for cimetidine on cancer cells that is independent of classical H2 receptor antagonism. Although both cimetidine and ranitidine are both H2 receptor antagonists, they are quite different structurally and possess different binding affinities at other sites (Lin, 1991) . It would seem likely that colon cancer cells carry histamine receptors different in structure to parietal type 2 receptors and these may lend themselves to the development of specific receptor antagonists.
Our cAMP studies certainly indicate that there is a receptor-mediated effect of histamine in colon cancer cells and the finding that cimetidine but not ranitidine affects histamine-stimulated cAMP release, in vitro and in vivo growth is strong evidence that this receptor systemresponsible for the histamine-stimulated growth and is other than a typical H2 receptor. Whether the functional histamine receptor of gastric cancer (Watson et al., 1993) and melanoma (Whitehead et al., 1988) are identical to C170 is unknown.
Previously, LIM2412 was demonstrated to be stimulated by histamine in vitro and inhibited by cimetidine in vivo (Adams et al., 1994a ). In the current experiments, histamine pumped into the opposite side of the tumour site produced a significant stimulation of tumour growth by 71.9% of the control. Ranitidine produced a significant in vivo stimulation in both experiments that appeared to be dose dependent (Figures 3 and 4) . We did not see evidence of in vitro stimulation (data not shown). The mechanism for this stimulation is uncertain and may not be H2 receptor mediated. In the current studies, cimetidine did not inhibit in vivo growth of LIM2412 but produced a significant stimulation. The reason for the variations in response of LIM2412 is not currently understood. This significant stimulation seen with ranitidine and cimetidine are clearly of concern and could be explained by agonist activity. Tutton and Barkla (1983) previously examined the effects of the H2 receptor antagonists cimetidine, metiamide and ranitidine on the growth of colonic tumours using two models -a carcinogen-induced rat model and fresh ex vivo tumours in thymectomised mice. In contrast to our results, there was significant inhibition in tumour growth by ranitidine given twice daily by intraperitoneal injection at a dose of 5 mg kg-' day-' whereas cimetidine had no effect. There are many differences in these experiments compared with the present series. We used oral rather than parenteral administration of drugs, and the doses of cimetidine we used were considerably higher than those used by Tutton and Barkla (1983) . Also our drug treatment commenced immediately after tumour inoculation, whereas Tutton and Barkla (1983) commenced treatment on day 24 after inoculation. Our studies with ranitidine used a greater dose range.
In addition to cell membrane receptors, intracellular histamine receptors have also been found to have important growth-controlling activity. Brandes and La Bella (1993) demonstrated binding by cimetidine and ranitidine to this intracellular histamine receptor to be both weak and equal (5 x 10-3 M) so this site is unlikely to account for the difference we have seen between cimetidine and ranitidine.
Halm et al. (1995) demonstrated that cimetidine, but not ranitidine or famotidine, has an immunomodulating effect on peripheral blood mononuclear cells in gastric cancer patients.
Again, this suggests that ranitidine and cimetidine have differing actions on non-parietal H2 receptors.
The survival advantage found in patients receiving cimetidine in gastric cancer (Tonneson et al., 1988) and trends to survival advantage from colorectal cancer, in three trials of different designs Svendsen et al., 1995; Matsumoto 1995) suggest a role for this drug as a non-toxic inhibitor of tumour growth. Our data, however, suggest that very different results may be achieved by some histamine antagonists in some circumstances. The possibly novel nature (non-classical H2) of the growth-regulating histamine receptor seen in at least some human colorectal cancers may allow development of more specific and hopefully even more active antagonists.
